Determining the potential clinical value of panel-based pharmacogenetic testing in patients with chronic pain or gastroesophageal reflux disease

被引：8
|
作者：
Elchynski, Amanda L. [1 ,2 ]
Cicali, Emily J. [1 ,2 ]
Ferrer del Busto, Maria C. [1 ]
Hamilton, Alessandra [1 ]
Chang, Ku-Lang [3 ]
Schmidt, Siegfried O. [3 ]
Weiner, Brian [4 ,7 ,8 ]
Davis, Richard [4 ]
Estores, David [4 ]
Max Smith, D. [5 ,6 ]
Wiisanen, Kristin [1 ,2 ]
Johnson, Julie A. [1 ,2 ]
Cavallari, Larisa H. [1 ,2 ]
机构：
[1] Univ Florida, Coll Pharm, Dept Pharmacotherapy & Translat Res, Gainesville, FL 02115 USA
[2] Univ Florida, Coll Pharm, Ctr Pharmacogen & Precis Med, Gainesville, FL 02115 USA
[3] Univ Florida, Coll Med, Dept Community Hlth & Family Med, Gainesville, FL USA
[4] Univ Florida, Div Gastroenterol Hepatol & Nutr, Gainesville, FL USA
[5] MedStar Hlth, Columbia, MD USA
[6] Georgetown Univ, Med Ctr, Dept Oncol, Washington, DC USA
[7] Florida Atlantic Univ, Charles E Schmidt Sch Med, Boca Raton, FL USA
[8] Cleveland Clin, Digest Dis Inst, Weston, FL USA
来源：
PHARMACOGENOMICS JOURNAL | 2021年 / 21卷 / 06期
关键词：
PREVALENCE;
D O I：
10.1038/s41397-021-00244-6
中图分类号：
Q3 [遗传学];
学科分类号：
071007 ; 090102 ;
摘要：
We aimed to determine the potential value of panel-based pharmacogenetic (PGx) testing in patients with chronic pain or gastroesophageal reflux disease (GERD) who underwent single-gene PGx testing to guide opioid or proton pump inhibitor (PPI) therapy, respectively. Of 448 patients included (chronic pain, n = 337; GERD, n = 111), mean age was 57 years, 68% were female, and 73% were white. Excluding opiates for the pain cohort and PPIs for the GERD cohort, 76.6% of patients with pain and 71.2% with GERD were prescribed at least one additional medication with a high level of PGx evidence, most commonly ondansetron or selective serotonin reuptake inhibitors. The most common genes that could inform PGx drug prescribing were CYP2C19, CYP2D6, CYP2C9, and SLCO1B1. Our findings suggest that patients with chronic pain or GERD are commonly prescribed drugs with a high level of evidence for a PGx-guided approach, supporting panel-based testing in these populations.
引用
收藏
页码：657 / 663
页数：7
相关论文
共 43 条
  • [1] Determining the potential clinical value of panel-based pharmacogenetic testing in patients with chronic pain or gastroesophageal reflux disease
    Amanda L. Elchynski
    Emily J. Cicali
    Maria C. Ferrer del Busto
    Alessandra Hamilton
    Ku-Lang Chang
    Siegfried O. Schmidt
    Brian Weiner
    Richard Davis
    David Estores
    D. Max Smith
    Kristin Wiisanen
    Julie A. Johnson
    Larisa H. Cavallari
    [J]. The Pharmacogenomics Journal, 2021, 21 : 657 - 663
  • [2] DETERMINING THE POTENTIAL VALUE OF PANEL-BASED PHARMACOGENETIC TESTING IN A CHRONIC PAIN POPULATION.
    Elchynski, A.
    Cicali, E.
    Chang, K.
    Nys, C.
    Elsey, A.
    Johnson, J.
    Wiisanen, K.
    Schmidt, S.
    Cavallari, L.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 107 : S14 - S14
  • [3] DETERMINING THE POTENTIAL VALUE OF PANEL-BASED PHARMACOGENETIC TESTING IN A CHRONIC PAIN POPULATION.
    Elchynski, A.
    Cicali, E.
    Chang, K.
    Nys, C.
    Elsey, A.
    Johnson, J.
    Wiisanen, K.
    Schmidt, S.
    Cavallari, L.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 107 : S56 - S56
  • [4] A Pharmacogenetic Panel-Based Prediction of the Clinical Outcomes in Elderly Patients with Coronary Artery Disease
    Dong, Lisha
    Zhang, Shizhao
    Lv, Chao
    Xue, Qiao
    Yin, Tong
    [J]. PHARMACEUTICS, 2024, 16 (08)
  • [5] An Integrated Approach to Deploy Panel-Based Pharmacogenetic Testing and Clinical Decision Support
    Pulk, Rebecca A.
    Hsiao, Allen L.
    Murray, Michael F.
    Stump, Lisa
    Schulz, Wade L.
    [J]. JOURNAL OF APPLIED LABORATORY MEDICINE, 2021, 6 (04): : 1094 - 1096
  • [6] Should we consider panel-based pharmacogenetic testing in gynecologic oncology patients?
    Mulugeta-Gordon, Lakeisha
    Haggerty, Ashley
    Ko, Emily
    Hoffecker, Glenda
    Tuteja, Sony
    Verma, Shefali
    Keat, Karl
    [J]. GYNECOLOGIC ONCOLOGY, 2022, 166 : S124 - S124
  • [7] Clinical utilization of panel-based molecular testing for patients with AML
    Aubrey, Brandon J.
    Brunner, Andrew
    [J]. HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2022, (01) : 30 - 33
  • [8] Individualized Therapy for Gastroesophageal Reflux Disease Potential Impact of Pharmacogenetic Testing based on CYP2C19
    Furuta, Takahisa
    Sugimoto, Mitsushige
    Shirai, Naohito
    [J]. MOLECULAR DIAGNOSIS & THERAPY, 2012, 16 (04) : 223 - 234
  • [9] Panel-Based Clinical Genetic Testing in 85 Children with Inherited Retinal Disease
    Taylor, Rachel L.
    Parry, Neil R. A.
    Barton, Stephanie J.
    Campbell, Christopher
    Delaney, Claire M.
    Ellingford, Jamie M.
    Hall, Georgina
    Hardcastle, Claire
    Morarji, Jiten
    Nichol, Elisabeth J.
    Williams, Lindsi C.
    Douzgou, Sofia
    Clayton-Smith, Jill
    Ramsden, Simon C.
    Sharma, Vinod
    Biswas, Susmito
    Lloyd, I. Chris
    Ashworth, Jane L.
    Black, Graeme C.
    Sergouniotis, Panagiotis I.
    [J]. OPHTHALMOLOGY, 2017, 124 (07) : 985 - 991
  • [10] Pharmacogenetic Testing: The Ethics of Implementing in Clinical Practice for Chronic Pain Patients
    Fredrikson, Karin M.
    Fasolino, Tracy
    [J]. JOURNAL OF PAIN & PALLIATIVE CARE PHARMACOTHERAPY, 2020, 34 (02) : 69 - 76
12345